Health care resource use and costs among patients with carcinoid syndrome in France: Analysis of the National Health Insurance Database.

Autor: Perrier M; Department of Digestive Oncology, ENETS Centre of Excellence, Edouard Herriot Hospital, Hospices Civils de Lyon, 69003 Lyon, France. Electronic address: mperrier@chu-reims.fr., Mouawad C; Ipsen Pharma, Boulogne Billancourt, France., Gueguen D; Ipsen Pharma, Boulogne Billancourt, France., Thomé B; Median conseil, Pau, France., Lapeyre-Mestre M; Department of Medical and Clinical Pharmacology, Toulouse University Hospital, Toulouse, France., Walter T; Department of Digestive Oncology, ENETS Centre of Excellence, Edouard Herriot Hospital, Hospices Civils de Lyon, 69003 Lyon, France.
Jazyk: angličtina
Zdroj: Clinics and research in hepatology and gastroenterology [Clin Res Hepatol Gastroenterol] 2023 Aug; Vol. 47 (7), pp. 102177. Date of Electronic Publication: 2023 Jul 14.
DOI: 10.1016/j.clinre.2023.102177
Abstrakt: Objectives: Carcinoid syndrome (CS) develops in approximately 20% of patients with neuroendocrine tumours (NET). This study described healthcare resource utilization and its associated costs among patients with NET and CS, using the French national health care data system.
Methods: Patients were included if they had a hospital stay associated with the code E34.0 "CS" and at least one delivery of a somatostatin analogue (SSA) between 01/01/2012 and 31/12/2016. The end of the analysis was either 31/12/2017 or the date of death, whichever occurred first. Mean overall costs were described by item of expenditure and by periods.
Results: 646 patients were included: 64yo, 55% men, 64% and 15% had NET from the small-intestine or lung, respectively. Among them, 309 patients were incident and 271 died during the study period. Mean overall cost per person per month (PPPM) was €2,892: €3,273 for the first year following diagnosis, €2,574 in "middle-years" and €5,039 within the year preceding death. The two most costly expenditure items were drugs (€1,695 PPPM) and hospital stays (€870 PPPM).
Conclusion: The first year following diagnosis and the year preceding death are the two periods representing the highest costs for CS care in France. Successful disease management may contribute to lower costs in the intermediate period.
Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: TW received financial support from IPSEN, AAA-Novartis, Keocyt, and Roche to conduct clinical trials and/or ancillary studies. CM and DG were Ipsen employees at the time of study conduct. MP, BT and MLM have no conflicts of interest to declare.
(Copyright © 2023 Elsevier Masson SAS. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: